- Home
- RVMD vs MRNA Comparison
RVMD vs MRNA Comparison
Compare RVMD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | MRNA |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 26.7B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RVMD | MRNA |
|---|---|---|
| Price | $208.19 | $145.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 12 |
| Target Price | ★ $140.84 | $34.27 |
| AVG Volume (30 Days) | 1.6M | ★ 16.7M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $533.02 | $15.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $35.62 | $22.28 |
| 52 Week High | $220.34 | $176.66 |
Technical Indicators
Market Signals| Indicator | RVMD | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 72.44 |
| Support Level | $177.04 | $41.01 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 7.36 | 10.94 |
| MACD | 0.46 | 10.45 |
| Stochastic Oscillator | 71.41 | 75.89 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.